Brian Slomovitz, MD, assistant professor, Columbia University Division of Hematology/Oncology, Mount Sinai Medical Center, Miami, and professor of Obstetrics and Gynecology, Florida International University, discusses the role of PARP inhibitors in the treatment of ovarian cancer. Dr Slomovitz frequently uses PARP inhibitor treatment in his practice, noting that women with ovarian cancer deserve to live longer. Despite some signal of detriment to overall survival indicated in studies with a large amount of crossover, recent studies have started to address whether there is any reason PARP inhibitors should be withheld from patients.